The Federal Pain Research Strategy recommended development of nonopioid analgesics as a top priority in its strategic plan to address the significant public health crisis and individual burden of chronic pain faced by .100 million Americans. Motivated by this challenge, a natural product extracts library was screened and identified a plant extract that targets activity of voltage-gated calcium channels. This profile is of interest as a potential treatment for neuropathic pain. The active extract derived from the desert lavender plant native to southwestern United States, when subjected to bioassay-guided fractionation, afforded 3 compounds identified as pentacyclic triterpenoids, betulinic acid (BA), oleanolic acid, and ursolic acid. Betulinic acid inhibited depolarization-evoked calcium influx in dorsal root ganglion (DRG) neurons predominantly through targeting low-voltage-gated (Cav3 or T-type) and CaV2.2 (N-type) calcium channels. Voltage-clamp electrophysiology experiments revealed a reduction of Ca 21 , but not Na 1 , currents in sensory neurons after BA exposure. Betulinic acid inhibited spontaneous excitatory postsynaptic currents and depolarization-evoked release of calcitonin gene-related peptide from lumbar spinal cord slices. Notably, BA did not engage human mu, delta, or kappa opioid receptors. Intrathecal administration of BA reversed mechanical allodynia in rat models of chemotherapy-induced peripheral neuropathy and HIV-associated peripheral sensory neuropathy as well as a mouse model of partial sciatic nerve ligation without effects on locomotion. The broad-spectrum biological and medicinal properties reported, including anti-HIV and anticancer activities of BA and its derivatives, position this plant-derived small molecule natural product as a potential nonopioid therapy for management of chronic pain.
Introduction
Chronic pain affects about 20% to 30% of the population worldwide. 33 In 2014, pain ranked 3rd in global therapy areas accounting for US prescription sales of $59.7 billion. 47 Opioids are the cornerstone of pain management for many types of pain. 20, 31, 84 However, opioids are only partially effective in some pain types and patient populations, including neuropathic pain, and are often associated with serious side effects-including tolerance, addiction, and death that limit their clinical utility. 3 In February 2018, the International Association for the Study of Pain stated "Opioids are indispensable for the treatment of severe short-lived pain" and "Currently, no other oral medication offers immediate and effective relief of severe pain." This highlights an urgent need for developing novel therapeutic strategies for the treatment of chronic pain.
Clinically used medications either originate from the repurposing of drugs initially designed for depression and epilepsy (gabapentin 17 and amitriptyline 2 ) or are natural products such as morphine and ziconotide. 81 In this context, it is noteworthy that the first opioid was not synthetic but derived from plants. We thus investigated whether using plant extracts could uncover novel natural compounds beneficial for pain. We screened 88 small In this study, we discovered that BA from H. emoryi is a novel natural inhibitor of N-and T-type voltage-gated Ca 21 channels. We further characterized this small molecule as a preferential inhibitor for Cav3.2 and Cav2.2. Betulinic acid had no inhibitory effect on voltage-gated Na 1 channels and did not show any binding to opioid receptors. We found that BA treatment resulted in the inhibition of miniature excitatory postsynaptic currents and of depolarization-evoked neurotransmitter release. Finally, we identified the antinociceptive potential of BA in preclinical rat models of chemotherapy-induced peripheral neuropathy (CIPN) and HIV sensory neuropathy as well as a mouse model of partial sciatic nerve ligation without effects on locomotion. Our results show the unexplored potential of small molecule natural plant extracts for chronic pain.
Methods

Animals
Pathogen-free, adult male and female Sprague-Dawley rats (225-250 g; Envigo, Huntingdon, United Kingdom) or female C57BL/ 6NHsd (22 g; Envigo) were housed in temperature-controlled (23 6 3˚C) and light-controlled (12-hour light/12-hour dark cycle; lights on 07:00-19:00) rooms with standard rodent chow and water available ad libitum. The Institutional Animal Care and Use Committee of the College of Medicine at the University of Arizona approved all experiments. All procedures were conducted in accordance with the Guide for Care and Use of Laboratory Animals published by the National Institutes of Health and the ethical guidelines of the International Association for the Study of Pain. Animals were randomly assigned to treatment or control groups for the behavioral experiments. Animals were initially housed 3 per cage but individually housed after the intrathecal (i.th.) cannulation on a 12-hour light-dark cycle with food and water ad libitum. All behavioral experiments were performed by experimenters who were blinded to the experimental groups and treatments.
Materials
All chemicals, unless noted, were purchased from Sigma (St. Louis, MO).
Analytical instrumentation, extraction, and isolation of betulinic acid
See supplementary methods, available at http://links.lww.com/ PAIN/A657.
Preparation of acutely dissociated dorsal root ganglion neurons
Dorsal root ganglia from all levels were acutely dissociated using methods as described previously. 28 Rat DRG neurons were isolated from 150-to 174-g Sprague-Dawley rats using previously developed procedures. 54 In brief, dorsal skin and muscle were removed and vertebral bone processes parallel to the dissection stage-exposed DRG were cut. Dorsal root ganglia were then collected, trimmed at their roots, and enzymatically digested in 3-mL bicarbonate-free, serum-free, sterile DMEM (Cat# 11965; Thermo Fisher Scientific, Waltham, MA) solution containing neutral protease (3.125 mg/mL, Cat#LS02104; Worthington, Lakewood, NJ) and collagenase type I (5 mg/mL, Cat# LS004194; Worthington) and incubated for 60 minutes at 37˚C under gentle agitation. Dissociated DRG neurons (;1.5 3 10 6 ) were then gently centrifuged to collect cells and washed with DRG media (DMEM containing 1% penicillin/streptomycin sulfate from 10,000 mg/mL stock, 30 ng/mL nerve growth factor, and 10% fetal bovine serum [HyClone] ) before plating onto poly-D-lysine-and laminin-coated glass 12-or 15-mm coverslips. All cultures were used within 48 hours.
Calcium imaging in acutely dissociated dorsal root ganglion neurons
Dorsal root ganglion neurons were loaded for 30 minutes at 37˚C with 3-mM Fura-2AM (Cat# F1221; Thermo Fisher, stock solution prepared at 1 mM in DMSO, 0.02% pluronic acid, Cat#P-3000MP; Life Technologies, Carlsbad, CA) to follow changes in intracellular calcium ([Ca 21 ] c ) in a standard bath solution containing 139-mM NaCl, 3-mM KCl, 0.8-mM MgCl 2 , 1.8-mM CaCl 2 , 10-mM Na HEPES, pH 7.4, and 5-mM glucose, exactly as previously described. 9 Fluorescence imaging was performed with an inverted microscope, Nikon Eclipse Ti-U (Nikon Instruments Inc, Melville, NY), using objective Nikon Fluor 4X and a Photometrics cooled CCD camera CoolSNAP ES 2 (Roper Scientific, Tucson, AZ) controlled by Nis Elements software (version 4.20; Nikon Instruments). The excitation light was delivered by a Lambda-LS system (Sutter Instruments, Novato, CA). The excitation filters (340 6 5 nm and 380 6 7 nm) were controlled by a Lambda 10 to 2 optical filter change (Sutter Instruments). Fluorescence was recorded through a 505-nm dichroic mirror at 535 6 25 nm. To minimize photobleaching and phototoxicity, the images were taken every ;10 seconds during the time course of the experiment using the minimal exposure time that provided acceptable image quality. The changes in [Ca 21 ] c were monitored by following a ratio of F 340 /F 380 , calculated after subtracting the background from both channels.
Dorsal root ganglia neuron transfection
Collected cells were resuspended in Nucleofector transfection reagent containing siRNA at 500 nM and 2 mg of the provided green fluorescent protein (GFP) plasmid as detailed previously. 21 Then, cells were subjected to electroporation protocol O-003 in an Amaxa Biosystem (Lonza, Basel, Switzerland) and plated onto poly-D-lysine-and laminin-coated glass 12-mm coverslips. Transfection efficiencies were routinely between 20% and 30% with ;10% cell death. Small diameter neurons were selected to target Ad-and c-fiber nociceptive neurons. For rat DRG culture, small cells were considered to be ;,30 mm as determined by an eyepiece micrometer within the objective lens. Successfully transfected cells were identified by GFP fluorescence. The siRNA sequences used were: CAGCCAUCUUCGUGGUGGAGAUGAU (for Cacna1h/Cav3.2; [Cat# RSS350286; Thermo Fisher]); CAGCAUCCUUGGGAUGCAUAUCUUU (for Cacna1i/Cav3.3; Cat# RSS367566); and siRNA Negative Control, Med GC was used as a scrambled siRNA control (Cat# 12935300).
Constellation pharmacology
These experiments were performed as described previously, 54, 77 but with the following modifications. Dorsal root ganglia neurons were loaded at 37˚C with 3-mM Fura-2AM for 30 minutes in Tyrode solution (at ;310 mOsm) containing 119-mM NaCl, 2.5-mM KCl, 2-mM MgCl 2 , 2-mM CaCl 2 , 25-mM HEPES, pH 7.4, and 30-mM glucose. After a 1-minute baseline measurement, Ca 21 influx was stimulated by the addition of the following receptor agonists: 400-nM menthol, 50-mM histamine, 10-mM adenosine triphosphate (ATP), 200-mM allyl isothiocyanate (AITC), 1-mM acetylcholine (ACh), and 100-nM capsaicin diluted in Tyrode solution. At the end of the constellation pharmacology protocol, cell viability was assessed by depolarization-induced Ca 21 influx using an excitatory KCl solution that comprised 32-mM NaCl, 90-mM KCl, 2-mM MgCl 2 , 2-mM CaCl 2 , 25-mM HEPES, pH 7.4, and 30-mM glucose. After the 1-minute baseline measurement, each trigger was applied for 15 seconds in the order indicated above in 6-minute intervals. After each trigger, bath solution was continuously perfused over the cells to wash off excess of the trigger. This process was automated using the ValveBank II perfusion system that controlled the perfusion of the standard bath solution and triggers (AutoMate Scientific, Berkeley, CA). For the BA condition, DRG were incubated overnight with a 20-mM concentration of the compound. Fluorescence imaging was performed under the same conditions noted above for calcium imaging. A cell was defined as a "responder" if its fluorescence ratio of 340 nm/380 nm was greater than 10% of the baseline value calculated using the average fluorescence in the 30 seconds preceding application of the trigger.
Semiquantitative real-time PCR
Semiquantitative real-time PCR was performed as described previously. 10, 55 After transfection with the indicated siRNA, RNA was extracted from cultured DRG using Tri reagent (Cat# TR118; MRC, Cincinnati, OH) according to the manufacturer's protocol. Briefly, tri reagent was added to the DRG. The homogenates were centrifuged at 5,000g for 5 minutes at 4˚C to eliminate insoluble materials, and chloroform was added to the supernatants at 20% (vol/vol). After centrifugation at 12,000g, 15 minutes, 4˚C, the upper, RNA-containing, aqueous fraction was harvested in a new tube and the total RNA was precipitated by adding isopropanol (50%, vol/vol). The precipitates were centrifuged at 20,000g, 10 minutes, 4˚C; then, the RNA pellet was washed twice with 75% ethanol. Finally, purified RNA was resuspended in ultrapure water and stored at 220˚C until analysis. To generate cDNA, 2 mg of purified RNA was retrotranscribed using Maxima Reverse Transcriptase (Cat# EP0743; Thermo Fisher) according to manufacturer's instructions. Quantitative real-time PCR analysis was performed using 5X HOT FIREPol EvaGreen (Cat# 08-24-00020; Solis BioDyne, Tartu, Estonia) on a CFX connect (BioRad, Hercules, CA) according to manufacturer's instructions. Validated primer sequences used were from 12 Activation of I Ca was measured by using a holding voltage of 290 mV with voltage steps 200 milliseconds in duration applied at 5-second intervals in 110-mV increments from 270 to 160 mV. Current density was calculated as peak I Ca /cell capacitance. Steady-state inactivation of I Ca was determined by applying an 800-millisecond conditioning prepulse (2100 to 220 mV in 110-mV increments) after which the voltage was stepped to 220 mV for 200 milliseconds; a 15-second interval separated each acquisition. Whole-cell voltage-clamp recordings were performed at room temperature (RT) using an EPC 10 Amplifier-HEKA as previously described. 22 The internal solution for voltage-clamp sodium current recordings contained (in millimolar): 140 CsF, 1.1 CsEGTA, 10 NaCl, and 15 HEPES (pH 7.3, 290-310 mOsm/L), and external solution contained (in millimolar): 140 NaCl, 3 KCl, 30 tetraethylammonium chloride, 1 CaCl 2 , 0.5 CdCl 2 , 1 MgCl 2 , 10 Dglucose, and 10 HEPES (pH 7.3, 310-315 mOsm/L). Dorsal root ganglion neurons were subjected to current density (I-V) and fast-inactivation voltage protocols as previously described. 21, 28 In the I-V protocol, cells were held at a 280 mV holding potential before depolarization by 20-millisecond voltage steps from 270 to 160 mV in 10-mV increments. This allowed for collection of current density data to analyze activation of sodium channels as a function of current vs voltage and also peak current density, which was typically observed near ;0 to 10 mV and normalized to cell capacitance (pF). In the fast-inactivation protocol, cells were held at a 280 mV holding potential before hyperpolarizing and repolarizing pulses for 500 milliseconds between 2120 to 210 mV in 5-mV increments. This step conditioned various percentages of channels into fast-inactivated states so that a 0-mV test pulse for 20 milliseconds could reveal relative fast inactivation normalized to maximum current. Firepolished recording pipettes, 2 to 5 MV resistance, were used for all recordings. Whole-cell recordings were obtained with a HEKA EPC-10 USB (HEKA Instruments Inc, Bellmore, NY); data were acquired with a Patchmaster (HEKA) and analyzed with a Fitmaster (HEKA). Capacitive artifacts were fully compensated, and series resistance was compensated by ;70%. Recordings made from cells with greater than a 5-mV shift in series resistance compensation error were excluded from analysis. All experiments were performed at RT (;23˚C).
The Boltzmann relation was used to determine the voltage dependence for activation of I Ca and I Na wherein the conductance-voltage curve was fit by the equation G/G max 5 1/[1 1 exp (V 0.5 2 V m )/k], where G is the conductance G 5 I/(V m 2 E Ca or E Na ), G max is the maximal conductance obtained from the Boltzmann fit under control conditions, V 0.5 is the voltage for half-maximal activation, V m is the membrane potential, and k is a slope factor. E Ca is the reversal potential for I Ca ; E Na is the reversal potential for I Na and was determined for each individual neuron. The values of I Ca and I Na around the reversal potential were fit with a linear regression line to establish the voltage at which the current was zero. The Boltzmann parameters were determined for each individual neuron and then used to calculate the mean 6 SEM.
Cell culture and transient transfection
Human embryonic kidney tsA-201 cells were cultured and transfected using the calcium phosphate method. Cells were plated on glass coverslips, and transfected with 3 mg of either of the channel cDNAs. Green fluorescent protein (0.5 mg) was added to the mix as a transfection reporter. All the experiments were performed 72 hours after cell transfection. Currents were evoked by applying 100-ms test pulses from a holding potential of 2100 to 230 mV. The effects of BA (20 mM) were assessed by normalizing the current amplitude in the presence of the drug to that observed during vehicle administration (0.1% DMSO).
Preparation of spinal cord slices
As described previously, 94 young rats (postnatal 10-14 days) were deeply anesthetized with diethyl ether and the lumbar region of the spinal column was quickly removed, euthanizing the animal. For spinal nerve blocking, 0.3 mL of 2% lidocaine was injected to both sides of L4 to 5 lumbar vertebrae. Laminectomy was performed from midthoracic to low-lumbar levels, and the spinal cord was quickly removed into cold modified artificial cerebrospinal fluid oxygenated with 95% O 2 and 5% CO 2 . The artificial cerebrospinal fluid contained (in millimolar): 80 NaCl, 2.5 KCl, 1.25 NaH 2 PO 4 , 0.5 CaCl 2 , 3.5 MgCl 2 , 25 NaHCO 3 , 75 sucrose, 1.3 ascorbate, and 3.0 sodium pyruvate, with pH at 7.4 and osmolarity at 310 mOsm. Transverse 350-mm thick slices were obtained by a vibratome (VT1200S; Leica, Nussloch, Germany). Slices were then incubated for at least 1 hour at RT in an oxygenated recording solution containing (in millimolar): 125 NaCl, 2.5 KCl, 2 CaCl 2 , 1 MgCl 2 , 1.25 NaH 2 PO 4 , 26 NaHCO 3 , 25 D-glucose, 1.3 ascorbate, and 3.0 sodium pyruvate, with pH at 7.4 and osmolarity at 320 mOsm. The slices were then positioned in a recording chamber and continuously perfused with oxygenated recording solution at a rate of 3 to 4 mL/min before electrophysiological recordings at RT.
Electrophysiological recording in spinal cord slices by whole-cell patch clamp
Substantia gelatinosa neurons in the superficial layers of the spinal dorsal horn were visualized and identified in the slices by means of infrared differential interference contrast video microscopy on an upright microscope (FN1; Nikon, Tokyo, Japan) equipped with a 3 3 40/0.80 water-immersion objective and a charge-coupled device camera. Patch pipettes with resistance at 6 to 10 MV were made from borosilicate glass (Sutter Instruments) on a 4-step micropipette puller (P-90; Sutter Instruments). The pipette solution contained the following (in millimolar): 120 potassium gluconate, 20 KCl, 2 MgCl 2 , 2 Na 2 -ATP, 0.5 Na-GTP, 20 HEPES, and 0.5 EGTA, with pH at 7.28 and osmolarity at 310 mOsm. The membrane potential was held at 2 60 mV using PATCHMASTER software in combination with a patch-clamp amplifier (EPC10; HEKA Elektronik, Lambrecht, Germany).
The whole-cell configuration was obtained in voltage-clamp mode. To record spontaneous excitatory postsynaptic currents (sEPSCs), bicuculline methiodide (10 mM) and strychnine (1 mM) were added to the recording solution to block g-aminobutyric acid-activated and glycine-activated currents, respectively. Hyperpolarizing step pulses (5 mV in intensity, 50 milliseconds in duration) were periodically delivered to monitor the access resistance (15) (16) (17) (18) (19) (20) (21) (22) (23) (24) (25) , and recordings were discontinued if the access resistance changed by more than 20%. For each neuron, sEPSCs were recorded for a total duration of 2 minutes. Currents were filtered at 3 kHz and digitized at 5 kHz. Data were further analyzed by the Mini Analysis (Synaptosoft Inc, Leonia, NJ) and Clampfit 10.7 Program. In all experiments, measurements were made from 1 neuron per slice. The amplitude and frequency of sEPSCs were compared between neurons from animals in control and BA groups.
Calcitonin gene-related peptide release from lumbar slices
Rats were deeply anesthetized with 5% isoflurane and then decapitated. Two vertebral incisions (cervical and lumbar) were made to expose the spinal cord. Pressure was applied to a saline-filled syringe inserted into the lumbar vertebral foramen, and the spinal cord was extracted. Only the lumbar region of the spinal cord was used for the calcitonin gene-related peptide (CGRP) release assay. Baseline treatments (#1 and #2) involved bathing the spinal cord in Tyrode solution. The excitatory solution consisting of 90-mM KCl was paired with the treatment for fraction #4. These fractions (10 minutes, 400 mL each) were collected for measurement of CGRP release. Samples were immediately flash-frozen and stored in a 220˚C freezer. Betulinic acid (20 mM) or vehicle (0.9% saline) was added to the pretreatment and cotreatment fractions (#3 and #4). The concentration of CGRP released into the buffer was measured by enzyme-linked immunosorbent assay (Cat# 589001; Cayman Chemical, Ann Arbor, MI).
Implantation of intrathecal catheter
For i.th. drug administration, rats were chronically implanted with catheters as described by Yaksh and Rudy. 87 Rats were anesthetized with halothane and placed in a stereotactic head holder. The occipital muscles were separated from their occipital insertion and retracted caudally to expose the cisternal membrane at the base of the skull. Polyethylene tubing was passed caudally from the cisterna magna to the level of the lumbar enlargement. Animals were allowed to recover and were examined for evidence of neurologic injury. Animals with evidence of neuromuscular deficits were excluded.
Testing of allodynia
The assessment of tactile allodynia (ie, a decreased threshold to paw withdrawal after probing with normally innocuous mechanical stimuli) consisted of testing the withdrawal threshold of the paw in response to probing with a series of calibrated fine (von Frey) filaments. Each filament was applied perpendicularly to the plantar surface of the paw of rodents held in suspended wire mesh cages. Withdrawal threshold was determined by sequentially increasing and decreasing the stimulus strength (the "up and down" method), and data were analyzed with the nonparametric method of Dixon, as described by Chaplan et al. 14 and expressed as the mean withdrawal threshold.
Radioligand binding cell lines and cell culture
The mu opioid receptor (MOR)-Chinese hamster ovary (CHO) cell line was purchased from PerkinElmer (#ES-542-C). The delta-OR (DOR) cell line was created and characterized in our laboratory, as reported in Ref. 73 . The kappa-OR (KOR) cell line was also created in our laboratory; an N-terminal 3X-hemagglutinintagged human KOR expression clone from Genecopoeia was electroporated into parental CHO cells and selected with 500-mg/ mL G418. The resulting selected population was enriched for receptor expression by live cell labeling with anti-HA-Alexa488 antibody and separating the top 2% of the population by flow cytometry. This high-expressing population was characterized by immunocytochemistry and Western blot to establish receptor expression and expected signal transduction activation. All 3 cell lines were characterized by saturation radioligand binding with 3 H-diprenorphine and the measured K D used in competition binding experiments to calculate the K I (MOR 5 5.23 nM; DOR 5 0.93 nM; KOR 5 1.81 nM; all the mean values of N $ 3 independent experiments). All cells were cultured in 50:50 DMEM/F12 media with 10% heat-inactivated fetal bovine serum and 1X penicillin/streptomycin supplement (all Gibco/Thermo Fisher brand) in a 37˚C humidified incubator with 5% CO 2 atmosphere; propagation cultures were further maintained in 500-mg/mL G418. Cultures were propagated for no more than 20 passages before discarding. Cell pellets for experiments were prepared by growth in 15-cm plates, harvest with 5-mM EDTA in Dulbecco's phosphate-buffered saline (no calcium or magnesium), and the storage of cell pellets at 280˚C before use.
Competition radioligand binding
Competition radioligand binding experiments were performed as reported in Ref. 73 . Membrane preparations of MOR-, DOR-, or KOR-CHO cells were combined with a fixed concentration of 3 Hdiprenorphine (MOR 5 5.33 nM; DOR 5 1.43 nM; KOR 5 1.95 nM) and a concentration curve of competitor ligand. These reactions were miniaturized to a 200-mL volume in 96-well plates. The reaction proceeded at RT for 60 minutes. The reactions were terminated by rapid filtration through 96-well format GF/B filter plates (PerkinElmer) with cold water, washed, dried, and MicroScint PS (PerkinElmer) added. The plates were read in a MicroBeta2 96-well format 6-detector scintillation counter (PerkinElmer). The data were normalized to the specific binding caused by 3 H-diprenorphine alone (100%) or nonspecific binding determined by a 10-mM concentration of known competitor ligand (0%; MOR 5 naloxone; DOR 5 SNC80; KOR 5 naloxone). K I values were calculated using the IC 50 
HIV-induced sensory neuropathy
Mechanical allodynia is produced by i.th. administration of the human immunodeficiency virus-1 (HIV-1) envelope glycoprotein, gp120. 52 Seven days after implantation of an i.th. catheter, baseline behavioral measurements were obtained and then rats were randomly assigned to 2 groups. On days 10, 12, and 14, rats were injected i.th. with 300 ng of gp120 (Cat#4961, HIV-1 BaL gp120 recombinant protein, NIH-AIDS Reagent program) in a final volume of 20 mL in 0.9% saline and 0.1% bovine serum albumin.
Paclitaxel-induced peripheral neuropathy
Rats were given paclitaxel (Cat# P-925-1; Goldbio, Olivette, MO) based on the protocol described by Polomano et al. 63 In brief, pharmaceutical-grade paclitaxel (Taxol) was resuspended at a concentration of 2 mg/mL in 30% 1:1 Cremophor EL: ethanol, 70% saline and given to the rats at 2 mg/kg intraperitoneally (i.p.) every other day for a total of 4 injections (days 0, 2, 4, and 6), resulting in a final cumulative dose of 8 mg/kg. No abnormal spontaneous behavioral changes in the rats were noted during or after the treatment. Animals developed mechanical hyperalgesia within 10 days after the first paclitaxel injection.
Partial sciatic nerve ligation
Partial sciatic nerve ligation was performed as described previously. 50 Briefly, mice were anesthetized under isoflurane. A cut was made through the skin to expose the right sciatic nerve. A partial ligation was made by tying one-third to one-half of the dorsal sciatic nerve. The right sciatic nerve of sham-operated mice was exposed, but ligation was not performed. Mice were monitored, adequately rehydrated, and kept in a controlled temperature (37˚C) until fully recovered from anesthesia.
Assessment of open-field behavior
Rats were randomly assigned to receiving the compound or its vehicle. Ninety to 180 minutes after i.th. injection of the compound or its vehicle, rats were placed in a round open field (diameter: 110 cm, walls: 35 cm) made of wood and painted black, under bright illumination. 64 Animals were allowed to behave freely in the apparatus for 10 minutes and their behavior was video-recorded. Total distance traveled, maximum speed, and time spent in the center of the apparatus (defined by a round 75-cm zone in the center of the apparatus) were analyzed by an automated activity monitoring software (Any-maze, Stoelting). All behavioral experiments were performed by experimenters who were blinded to experimental groups and treatments.
Statistical analyses
All values represent the mean 6 SEM, unless noted otherwise. All data were first tested for a Gaussian distribution using a ShapiroWilk test (GraphPad Prism 7 Software). The statistical significance of differences between mean values was determined by either Student t test or parametric analysis of variance followed by post (Fig. 1A) was found to have promising potential to decrease depolarizationevoked Ca 21 influx in rat DRG sensory neurons. Bioactivityguided fractionation of this extract by solvent-solvent partitioning with chloroform and 50% aqueous methanol yielded 2 fractions, F1 and F2 (Fig. 1B) . We next tested these by Ca 21 imaging (Fig.  1C) 83 ( Fig. 1D) . Extract and fractions were tested at concentrations of 440 mg/mL for H. emoryi extract and 88.4 mg/mL for F1 and F2. Fraction F1 specifically inhibited 40-mM KCl-evoked Ca 21 influx in rat DRG neurons (55.4 6 2.1% inhibition compared with 0.1% DMSO control, n 5 188-482 neurons analyzed), whereas fraction F2 did not show any inhibitory potential for either KCl concentrations (Fig. 1E) . These results show the potential presence of a natural compound inhibitor of voltage-gated Ca 21 channels (possibly T-type) in fraction F1 derived from H. emoryi extract.
Selection of betulinic acid for inhibition of depolarization-evoked calcium influx in rat dorsal root ganglia
Further separation of the active fraction F1 by HPLC yielded 3 pure compounds, identified as BA, oleanolic acid (OA), and ursolic acid (UA) (Fig. 2 and supplementary methods; available at http://links.lww.com/PAIN/A657). We tested the 3 compounds BA, UA, and OA using the same Ca 21 imaging protocol as described above to identify the small molecule responsible for voltage-gated Ca 21 channel inhibition in DRG sensory neurons ( Figs. 2A and B) . Rat sensory neurons were treated with 20 mM of BA, UA, or OA (Fig. 2C) (Fig. 2E) . Oleanolic acid and UA did not significantly inhibit Ca 21 influx for either of the KCl challenges (Figs. 2D and E) . Ursolic acid-treated neurons showed an increase (198.7 6 9.1% when triggered with 40-mM KCl and 174.3 6 4.1% when triggered with 90 mM KCl compared to 0.1% DMSO control, n 5 129) of K 1 -evoked Ca 21 influx. The opposing effects of UA and the inhibitory effects of BA on low-(preferential) and high-voltage-activated Ca 21 channels supported use of BA, as opposed to the extract, for the studies below.
Betulinic acid inhibits Ca 21 currents in rat dorsal root ganglia
We then investigated the effects of BA on total Ca 21 currents in rat DRG sensory neurons. Neurons were treated overnight with a 20-mM concentration of BA or control (0.1% DMSO) as indicated and Ca 21 currents were subsequently recorded (Fig.  3) . When compared with the control (0.1% DMSO), BA-treated neurons exhibited a 51.4% inhibition of total Ca 21 current (Fig.  3C) . No change in biophysical properties of Ca 21 currents was observed in BA-treated sensory neurons (Fig. 3D) . This inhibition in Ca 21 currents, consistent with the above shown inhibition of KCl-evoked Ca 21 influx, confirmed the function of BA as an inhibitor of voltage-gated calcium channels.
To specifically examine whether voltage-gated calcium (ie, T-type) channels were affected by BA, we pharmacologically isolated T-type currents using blockers of all other channels 21 currents were elicited from a holding potential of 290 mV to depolarizing test potentials (ranging from 260 to 150 mV in 5-mV increments) for 200 ms. Figure 3E shows representative voltage-dependent inward currents (I Ba ) from DRG neurons with fast kinetic properties (ie, T-type) similar to those reported previously. 79 Compared with control (0.1% DMSO), BA-treated neurons exhibited an ;50% inhibition of Ttype Ca 21 currents (Figs. 3F and G) . Thus, the data show inhibition of both high-and low-voltage-activated calcium channels by BA.
Betulinic acid inhibits Cav3.2 and Cav3.3 T-type Ca 21 channels
The above experiments identify the natural small molecule BA as an inhibitor of voltage-gated Ca 21 channels. As earlier results (Fig. 2) showed predominant block of low-voltageactivated channels evoked by 40-mM KCl depolarization, we initially focused our efforts on T-type channels. In DRG sensory neurons, the a subunits of Cav3.2 and Cav3.3 represent the majority of T-type Ca 21 channels. 90 To test if BA could preferentially target a specific T-type Ca 21 channel subunit, we used a knockdown strategy (using short interfering RNA [siRNA]) to eliminate either Cav3.2 or Cav3.3 in DRG sensory neurons (Fig. 4) . Dorsal root ganglion neurons were electroporated with the indicated siRNA (or a scrambled negative control) in combination with a GFP expressing plasmid (to identify transfected cells) (Fig. 4A) . The cells were cultured for 24 hours before adding 20 mM of BA overnight (or 0.1% DMSO as control) and then tested using 40-mM KCl as a trigger (Fig. 4A) . In scramble siRNA-transfected cells, BA strongly inhibited 40-mM KCl-evoked Ca 21 influx (Fig. 4B) (Fig. 4C) , BA failed to inhibit further the 40-mM KCl-evoked Ca 21 influx. To complement these data, we explored the inhibitory effect of BA on tsA-201 cells individually transfected with either Cav3.1, Cav3.2, or Cav3.3 (Fig. 5) . Betulinic acid (20 mM) was applied to the transfected cells and the indicated Cav3.x currents were recorded (Fig. 5A) . We found that BA had no inhibitory effect on Cav3.1 (Fig. 5B) , whereas this natural compound inhibited Cav3.2 ( Fig. 5C ) and Cav3.3 (Fig. 5D) currents. The comparison of the percentage of Cav3.x current inhibition elicited by BA treatment revealed a stronger inhibitory effect on Cav3.2 than on Cav3.3 (Fig. 5E) . Maximal inhibition of Cav3.2 was observed with 20-mM BA, although no further inhibition was observed with a doubling of the compound; we could not test higher concentrations because 0.2% DMSO by itself was inhibitory ( Table 1) . For Cav3.3, a maximal ;31% inhibition was observed with either the 20 or 40 mM concentrations of BA. Consistent with the above data in DRG, 20-mM BA also inhibited Cav2.2 currents by 69.8 6 2.5% (n 5 4) in tsA-201 cells (Figs. 5F and G) . Thus, we conclude that BA preferentially inhibits Cav3.2 (T-type) and Cav2.2 (N-type) Ca 21 channel subunits.
Betulinic acid's effect on the functional landscape of dorsal root ganglion sensory neurons
The results presented thus far collectively demonstrate the potential for inhibition of Ca 21 influx by BA through control of Cav3.2 and Cav3.3 T-type Ca 21 channels. These results do not uncover cell-specific neuronal classes that may be targeted by BA. We used the previously described constellation pharmacology protocol 76, 77 to explore cell-specific functionality as a result of key signaling proteins that define precise cell types. The constellation pharmacology assay poses 6 successive stimulations, each 6 minutes apart, to compare Ca 21 influx due to activity of Ca 21 -associated membrane proteins: Ca 21 -permeable ligand-gated ion channels, metabotropic receptors, and voltage-gated Ca 21 channels. After these 6 challenges, KClevoked response due to membrane depolarization is used to assess viability of neurons; neurons not responsive to KCl are excluded from analysis.
The heterogeneity of neuronal responsivity is demonstrated through example traces of sensory neurons treated with control (0.1% DMSO) and with a 20-mM concentration of BA (Figs. 6A  and B) as indicated. Notably, inhibition of depolarization-evoked Ca 21 influx was again inhibited as a result of treatment with BA; this is consistent with our previous data (Figs. 2 and 3) . Sensory neurons were incubated overnight with the specified treatment, control (n 5 761), or BA (n 5 835), and subsequently imaged with constellation pharmacology protocol. Data were collected from 3 independent experiments, and individual neuronal responses to each constellation trigger were analyzed. Neurons with responses under 10% of baseline fluorescence were excluded from our analyses.
We first inquired how treatment with BA would change overall functionality of sensory neurons. To test this, we assessed whether the response of neurons to the number of stimulatory challenges, independently of which specific agonists triggered response, was altered in response to BA treatment (Fig. 6C) . Compared to control-treated cells, more cells treated with BA responded to 2 stimulatory challenges and few cells responded to only 1 challenge. Next, we asked whether BA affected the sensitivity of DRG to the different constellation triggers, by analyzing the percent of cells responding to a specific receptor agonist, independently of any other constellation triggers these neurons may have responded to (Fig. 6D) . Furthermore, more functional cell subclasses were present in the population of neurons treated with BA (39 different functional classes) in comparison to the control population (30 different functional classes) (Fig. 6E) . This analysis showed that treatment with BA increases sensitivity to ATP stimulation. Overall, BA increased functional competence of cells.
In a more specific inquiry, we also explored how BA altered the extent of Ca 21 influx after specific stimulation by each constellation trigger. Thus, we analyzed peak Ca 21 responses (Fig. 6F) responses due to stimulation by any of the constellation triggers, the AUC of Ca 21 response due to stimulation by ACh and ATP was increased, and AUC of Ca 21 response due to stimulation by AITC was decreased in BA-treated neurons (Fig. 6G) . Stimulation by histamine, menthol, or capsaicin did not alter the AUC of Ca 21 response in sensory neurons after treatment with BA (Fig. 6G) .
We then asked whether BA-mediated inhibition of depolarization-evoked Ca 21 response would be altered in a functional class-specific manner. To test this, we assessed average peak Ca 21 response due to KCl challenge in sensory neurons that specifically responded to a particular constellation trigger, independent of any other constellation triggers they might have responded to. Treatment with BA significantly decreased KCl-evoked Ca 21 response in sensory neurons that responded to an ATP stimulus. However, DRG that responded to ACh, AITC, histamine, menthol, and capsaicin did not have altered KClevoked response due to BA treatment (Fig. 6H) . These results assist in uncovering the mechanism of Ca 21 inhibition by BA and warrant further exploration into the potential for BA as an antinociceptive agent.
Betulinic acid does not bind to the orthosteric site of the opioid receptors
To confirm that BA does not produce potential antinociception through off-target binding to the opioid receptors, we performed competition radioligand binding at all 3 opioid receptors in vitro. We competed BA and a positive control compound (naloxone for MOR and DOR, U50,488 for KOR) vs a fixed concentration of 3 H-diprenorphine in CHO cells Table 1 Table summarizing percent inhibition of Cav3.x currents by the indicated concentrations of betulinic acid (BA).
hCaV3.1 n.t.* n.t. expressing the human m (MOR), d (DOR), or k (KOR) opioid receptor. We found that BA did not bind to any opioid receptor up to a 10-mM concentration (Figs. 7A-C) . By contrast, the positive control compounds bound to all 3 targets with expected affinity (Figs. 7A-C) . These results strongly suggest that BA is not engaging the opioid receptors and that potential antinociception would thus not be as a result of opioid receptor association.
Sodium currents are resistant to betulinic acid
To further explore the mechanism of BA, we investigated its possible effect on voltage-gated Na 1 channel currents in rat sensory neurons. Sensory neurons were treated overnight with a 20-mM concentration of BA or control (0.1% DMSO) as indicated, and subsequently recorded (Figs. 8A and B) . In comparison with the control, sensory neurons exhibited no change in both total sodium current density and TTX-sensitive current density (Fig. 8C) after BA treatment. Biophysical properties of Na 1 currents in sensory neurons treated with BA remained unaltered compared with 0.1% DMSO control (Fig. 8D) .
Betulinic acid inhibits spontaneous electric postsynaptic currents through presynaptic suppression
Because T-and N-type calcium channels contribute to action potential firing and neurotransmitter release, 13 we performed electrophysiological recordings in substantia gelatinosa neurons in the superficial layers (within laminae I-II) of the spinal dorsal horn (Fig. 9A) to measure whether BA could inhibit sEPSCs. There was no significant decrease in sEPSC amplitude (postsynaptic effect) (Fig. 9C) or input resistance (Fig. 9E ) of neurons treated with 0.1% DMSO or BA (20 mM). However, BA treatment decreased sEPSC frequency (DMSO, 2.18 6 0.24 Hz; BA, 1.26 6 0.25 Hz, P , 0.05) (Fig. 9D) , suggesting presynaptic suppression of neurotransmitter release by BA.
Betulinic acid inhibits potassium-evoked neuropeptide release in spinal cord ex vivo
Presynaptic release of the neurotransmitter CGRP from sensory neurons is a known mediator of pronociceptive neuronal signaling. 57 Therefore, we investigated whether or not BA inhibited depolarization-evoked CGRP release from rat spinal cord. To test this, we used an ex vivo method for evoked CGRP release from the lumbar region of rat spinal cord. Enzyme-linked immunosorbent assay was used to measure CGRP content; samples were collected every 10 minutes. Basal CGRP levels were 1.85 6 0.32 pg/mL/mg of tissue (Fig.  10, fractions #1 & 2) . Vehicle (0.1% DMSO) or a 20-mM concentration of BA was added (Fig. 10, fraction #3) 10 minutes before stimulation with 90-mM KCl (Fig. 10, fraction  #4) . Treatment with BA did not elicit any CGRP release from the spinal cords (Fig. 10, fraction #3 ). Under depolarization, treatment with BA resulted in a ;40% decrease (evoked CGRP level for vehicle was 53.89 6 9.9 and for BA was 32.10 6 6.97 pg/mL/mg of tissue) of the depolarization-evoked increase in CGRP release seen in vehicle-treated tissue (Fig.  10, fraction #4) . These results show that inhibiting T-type voltage-gated Ca 21 channels with BA results in decreased depolarization-evoked CGRP release.
Chemotherapy-induced peripheral neuropathy is alleviated by treatment with betulinic acid
The above results identify BA as a novel compound inhibiting Ttype voltage-gated Ca 21 channels with a preference for Cav3.2 and Cav3.3. These channels are known to participate in neuropathic pain signal transmission. 34, 37, 69 In a model of CIPN, increased Cav3.2 expression underlies the painful behavior induced by paclitaxel administration. 46 We next tested whether Cav3.2 inhibition by BA could be beneficial to reverse nociceptive behaviors in a rat model of paclitaxel-induced peripheral neuropathy. Rats received 4 injections of paclitaxel (2 mg/kg) and developed mechanical allodynia as measured by decreased paw withdrawal threshold (Fig. 11A) . We injected BA (2 mg/5 mL, i.th.) and observed a significant reversal of mechanical allodynia at 1 hour after injection (Fig. 11A) . This effect lasted for 2 additional hours (Fig. 11A) before returning back to predrug baseline. Area under the curve showed a significant antinociceptive effect of BA compared with vehicle (saline)-injected animals (Fig. 11B) . These results show that BA has the potential for pain relief in paclitaxelinduced peripheral neuropathy.
Betulinic acid reverses HIV-induced sensory neuropathy behavior in rats
Sensory neuropathy is a frequent complication of HIV infection. 51 Because voltage-gated Ca 21 channels have previously been found to contribute to neuropathic pain, 34, 37, 61, 69 we investigated the potential of BA to provide antinociception in HIV-induced sensory neuropathy. To test this, we submitted the rats to 3 i.th. injections of the HIV-1 envelope glycoprotein (gp120) resulting in the development of mechanical allodynia. 52, 56, 89 Intrathecal injection of BA (2 mg/5 mL, i.th.) reversed mechanical allodynia at 2 and 3 hours (Fig. 11C) . This reversal of mechanical allodynia is supported by a significant increase of the AUC between BAtreated compared with vehicle (saline)-treated animals (Fig. 11D) . We conclude that BA has an antinociceptive potential for HIVinduced sensory neuropathy.
Betulinic acid reverses partial sciatic nerve ligation-induced sensory neuropathy behavior in mice
To explore the species and sex-related effects of BA in known animal pain models, we i.th. administered BA 7 days after partial sciatic nerve ligation (pSNL) or sham surgeries in female C57BL/ 6NHsd mice. Partial sciatic nerve ligation surgery evokes neuropathic pain in animals 50 and has been reported to involve plasticity in Cav2.2-mediated calcium currents. 88 Animals receiving a pSNL or sham surgery were administered i.th. (through a lumbar puncture) 0.1% DMSO or BA (2 mg/5 mL). Betulinic acid had no effect on mechanical allodynia in sham mice, but significantly reversed mechanical allodynia at 2 and 3 hours after pSNL surgery (Fig. 12A) . Area under the curve analysis also revealed a reversal in mechanical allodynia in pSNL mice treated with BA (Fig. 12B) . Thus, we conclude that BA acts to suppress pSNL-induced neuropathic pain.
Systemic administration of betulinic acid is ineffective in reducing paclitaxel-induced mechanical allodynia
To further assess BA's efficacy in the model of CIPN, we tested BA through i.p. injection at 2 doses (5 mg/kg and 20 mg/kg). However, we found that BA failed to significantly reverse paclitaxel-induced mechanical allodynia at both of these doses ( Fig. 13) . These experiments were largely limited by the solubility of the compound because BA is fairly insoluble. At doses higher than 20 mg/kg, BA precipitated out of solution, and thus we propose that systemic administration of BA is ineffective in this paclitaxel model due to a dose-limiting issue. Because BA could be a lead compound, on which effective antinociceptive drugs may be modeled, the insolubility of BA must be taken into account when developing future pharmacotherapies based on this natural compound.
Betulinic acid has no effects on sedation or locomotion in the open-field test
To assess whether BA had any effects on sedation or locomotion at therapeutic doses, we injected rats i.th. with 0.1% DMSO or BA (2 mg/5 mL, i.th.) and monitored their activity in the open-field test. Here, we chose rats treated with paclitaxel to assess whether BA had any beneficial effect on locomotion. Importantly, BA treatment did not modify total distance traveled, time in center zone, or the rats' maximum speed, suggesting that this compound does not affect exploratory behavior, anxiety, and locomotor activity, respectively, in animals previously treated with paclitaxel ( Fig. 14) .
Discussion
The results described here uncovered a new role for the natural product BA in antinociception in experimental models of neuropathic pain. We elucidated signaling mechanisms responsible for these effects of BA providing evidence for inhibition of low-voltage-activated (Cav3, T-type) channels and release of CGRP. Importantly, we also showed that BA does not inhibit sodium channels nor does it engage opioid receptors. The present findings provide compelling evidence that blockade of Cav3.2, Cav3.3, and Cav2.2 by BA is sufficient to reverse mechanical allodynia induced by 3 neuropathic pain states without any motoric effects and further substantiate the development of BA as a possible naturally derived therapeutic for chronic pain.
T-type Ca 21 channels are low-voltage-activated calcium channels (Cav3) with a half-activation voltage of ;245 mV. 79 They conduct relatively small and transient currents that support their involvement in neuronal excitability. Mammals express 3 different T-type calcium channel a1 subunitsCav3.1, Cav3.2, and Cav3.3-with overlapping pharmacological properties, but somewhat distinct biophysical properties and distributions. 42, 45 The predominant Cav3 channel isoform involved in pain signaling is Cav3.2, 4, 6 with expression in specific subpopulations of primary afferent neurons. 27 T-type Ca 21 channel activity is increased in afferent pain fibers in various chronic pain states, such as traumatic nerve injury, diabetic neuropathy, and chemotherapy-induced neuropathies. 91 Given the roles of these channels in regulating afferent fiber excitability and synaptic function in the spinal dorsal horn and their dynamic regulation during pain states, it is likely that blocking or depleting Cav3.2 channels in these tissues should mediate analgesic effects. 7 Silencing of Cav3.2 calcium channels (but not Cav3.1 or Cav3.3 channels) protects from mechanical hypersensitivity in nerve-injured mice. 6 Intrathecal administration of antisense oligonucleotide of Cav3.2 and Cav3.3, but not Cav3.1, significantly relieved tactile allodynia and thermal hyperalgesia in rats with chronic compression of the DRG. 82 (Fig. 3) , the modest inhibition of calcium influx evoked by 90-mM KCl (Fig. 2) , which presumably recruits highvoltage-activated calcium channels, including N-type, 83 and the inhibition of N-type calcium channel current in tsA-201 cells (Fig. 5) . The inhibition of sEPSC frequency, but not amplitude, further supports a presynaptic mechanism for BA. Multiple lines of evidence suggest that BA has broad-spectrum actions and is thus important in diverse biological pathways. For example, BA has been reported to possess anticancer, antiviral, anti-HIV, anti-inflammatory, antileukemic, antidiabetic, antihyperlipidemic, antibacterial, and antimycobacterial activities. 5, 25, 26, 38, 41, 71, 85, 86, 93 Betulinic acid has also been shown to be effective in reducing effects of metabolic syndrome and preventative in diabetic nephropathy. 1, 65 It was reportedly protective against ischemic complications as well as a potential therapy for Alzheimer's disease, atherosclerosis, and other vascular diseases. 35, 36, 59 Betulinic acid promotes osteogenesis and inhibits adipogenesis. 11 Our study is the first to demonstrate an antinociceptive activity of BA in neuropathic pain. It is tempting to speculate that the antinociceptive actions of BA in reversing mechanical allodynia in gp120-induced model of HIV-induced peripheral neuropathy may, in part, be due to its action as an HIV-1 entry inhibitor. 85 Thus, by intervening with both HIV-1's viral activity and associated neuropathy, BA might serve as a disease-modifying therapy to provide more than just symptomatic relief.
Although BA is broadly effective, its poor solubility in aqueous environments, limited half-life, 67, 68 and complex purification protocols 74 have precluded its development as a therapeutic. To work around these limitations of BA, studies have focused on enhancing the half-life and solubility of the compound by using delivery systems such as nanoparticles, nanoemulsions, liposomes, etc. 66 Yet others are structurally modifying BA to identify derivatives that have anti-HIV/ anticancer activity with improved pharmacokinetic profiles and high safety index. 
